Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence
Open Access
- 23 July 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 85 (1006) , 414-421
Abstract
Studies show reduced forced expiratory volume in 1 s (FEV1) in patients with chronic obstructive pulmonary disease (COPD) is an important independent predictor of cardiovascular death and is characterised by both pulmonary and systemic inflammation. Evidence shows statins have important anti-inflammatory effects in both the lungs and arteries. Although randomised control trials are yet to be reported, non-randomised studies have consistently shown benefit in COPD patients taking statins compared with those not. These include reductions in both cardiovascular and respiratory morbidity/mortality. Other potential benefits include a reduced decline in FEV1 and reduced risk of lung cancer. It is argued that confounding by a “healthy user effect” is unlikely to explain the observed benefit. Given the undisputed benefit of statins in high risk populations and the growing body of data suggesting statins may benefit patients with COPD, the question arises “Should statins be considered more often in patients with COPD?”.Keywords
This publication has 91 references indexed in Scilit:
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1Nature Genetics, 2008
- Statins and Cancer RiskThe American Journal of Medicine, 2008
- The Association Between Statins and Cancer Incidence in a Veterans PopulationJNCI: Journal of the National Cancer Institute, 2008
- Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular ArenaCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2008
- Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint CommitteeThorax, 2007
- TNFpolymorphisms modify endotoxin exposure-associated longitudinal lung function declineOccupational and Environmental Medicine, 2007
- The lesser known effects of statinsBMJ, 2006
- Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort studyBMJ, 2006
- Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary DiseaseJACC, 2006